Rx Product News

Published Online: Monday, February 17, 2014
Follow Pharmacy_Times:


Marketed by: H. Lundbeck A/S and Takeda Pharmaceuticals America, Inc
Indication: The FDA has approved Brintellix (vortioxetine) for treating adults with major depressive disorder. The recommended starting dose is 10 mg orally once daily without regard to meals; the dose should then be increased to 20 mg/ day, as tolerated. Brintellix can be discontinued abruptly; however, it is recommended that doses of 15 or 20 mg/day be reduced to 10 mg/day for 1 week before full discontinuation.
Dosage Form: Immediate-release tablets: 5, 10, 15, and 20 mg
For More Information: www.us.brintellix.com

Marketed by:
Bayer HealthCare Pharmaceuticals, Inc
Indication: The FDA has approved Adempas (riociguat), a soluble guanylate cyclase stimulator, to treat adults with (1) persistent/ recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class or (2) pulmonary arterial hypertension to improve exercise capacity, improve WHO functional class, and delay clinical worsening. Treatment should be initiated at a dosage of 1 mg 3 times a day.
Dosage Form: Tablets: 0.5, 1, 1.5, 2, and 2.5 mg
For More Information: www.adempas-us.com

Marketed by:
Indication: The FDA has approved Duavee (conjugated estrogens/bazedoxifene) for the treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause and for the prevention of postmenopausal osteoporosis. The recommended dose is 1 tablet by mouth once daily. Women taking Duavee should not take additional estrogens. Duavee should be used for the shortest duration consistent with the treatment goals and risks for the individual female patient.
Dosage Form: Tablets (conjugated estrogens/bazedoxifene): 0.45 mg/20 mg
For More Information: www.pfizerpro.com/hcp/duavee

Marketed by:
Teva Pharmaceuticals USA, Inc
Indication: Adasuve (loxapine) inhalation powder is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Adasuve must be administered only by a health care professional. Before administration, all patients must be screened for a history of pulmonary disease and examined for respiratory abnormalities. Only a single 10-mg dose of Adasuve should be administered within a 24-hour period, by oral inhalation using the single-use inhaler.
Dosage Form: Inhalation powder: 10 mg
For More Information: www.adasuve.com

Related Articles
Acquisition Provides Pfizer with a Preclinical CMV Vaccine Candidate
A phase 3 study showed that Pfizer’s pregabalin controlled-release formulation holds promise in adult patients with postherpetic neuralgia, the manufacturer announced in a press release.
Mylan Inc. announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.
Actavis plc today announced that it has launched a generic version of Celebrex® 50 mg, 100 mg, 200 mg and 400 mg capsules, as part of a settlement agreement with Pfizer, Inc.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times